Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Multiple Myeloma"" wg kryterium: Temat


Starter badań:

Tytuł:
Defects and countermeasures in laboratory diagnosis of rare IgE multiple myeloma.
Autorzy:
Chen Y; Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China.
Chen Y; Pittsburgh Institute, Sichuan University, Chengdu, Sichuan 610225, China.
Zhou Y; Department of Clinical Laboratory, Zhejiang Xiaoshan Hospital, Hangzhou, Zhejiang 311200, China.
Zho F; Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China.
Wang S; Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China.
Zheng S; Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China.
Shen Y; Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China.
Tong X; Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China. Electronic address: .
Du J; Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital (Affiliated People's Hospital, Hangzhou Medical College), Hangzhou, Zhejiang 310014, China. Electronic address: .
Li Y; Department of Central Laboratory, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310006, China. Electronic address: .
Pokaż więcej
Źródło:
Clinica chimica acta; international journal of clinical chemistry [Clin Chim Acta] 2022 Jul 01; Vol. 532, pp. 37-44. Date of Electronic Publication: 2022 May 17.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Smoldering Multiple Myeloma*
Clinical Laboratory Techniques ; Humans ; Immunoglobulin E ; Immunoglobulin Light Chains ; Immunoglobulin kappa-Chains ; Immunoglobulin lambda-Chains ; Protein Aggregates
Czasopismo naukowe
Tytuł:
Exosomal circ-CACNG2 promotes cardiomyocyte apoptosis in multiple myeloma via modulating miR-197-3p/caspase3 axis.
Autorzy:
Yu M; Department of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, 16369 Jingshi Road, Jinan, 250014, China.
Ji L; Department of Neurology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, 250001, China.
Li S; Department of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, 16369 Jingshi Road, Jinan, 250014, China.
Zhang Y; Department of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, 16369 Jingshi Road, Jinan, 250014, China.
Sun X; Department of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, 16369 Jingshi Road, Jinan, 250014, China.
Sun R; Department of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, 16369 Jingshi Road, Jinan, 250014, China.
Chen X; Department of Health Care, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, 250014, China.
Luo Y; Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, 250014, China.
Cui X; Department of Oncology and Hematology, The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong Province, 250001, China. Electronic address: .
Pokaż więcej
Źródło:
Experimental cell research [Exp Cell Res] 2022 Aug 15; Vol. 417 (2), pp. 113229. Date of Electronic Publication: 2022 May 29.
Typ publikacji:
Journal Article
MeSH Terms:
MicroRNAs*/genetics
MicroRNAs*/metabolism
Multiple Myeloma*/genetics
Multiple Myeloma*/pathology
Apoptosis/genetics ; Calcium Channels ; Caspase 3/metabolism ; Cell Proliferation/genetics ; Humans ; Myocytes, Cardiac/metabolism ; RNA, Circular/genetics
Czasopismo naukowe
Tytuł:
Describing IgA Myeloma: An Immunophenotypic and Molecular Approach.
Autorzy:
Akgun Y; Department of Pathology and Laboratory Medicine, University of Miami and Jackson Health System, Miami, Florida.
Baykara Y; Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, The Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Hacking SM; Department of Pathology and Laboratory Medicine, The Warren Alpert Medical School of Brown University; Department of Pathology and Laboratory Medicine, Donald and Barbara Zucker School of Medicine at Northwell.
Langlie J; University of Miami Miller School of Medicine, University of Miami and Jackson Health System, Miami, Florida.
Huberman MA; University of Miami Miller School of Medicine, University of Miami and Jackson Health System, Miami, Florida.
Espejo AP; Department of Hematology and Medical Oncology, University of Miami, Jackson Health System, Miami, Florida.
Chapman J; Department of Pathology and Laboratory Medicine, University of Miami and Jackson Health System, Miami, Florida.
Poveda J; Department of Pathology and Laboratory Medicine, University of Miami and Jackson Health System, Miami, Florida.
Pokaż więcej
Źródło:
Rhode Island medical journal (2013) [R I Med J (2013)] 2022 Aug 01; Vol. 105 (6), pp. 41-45. Date of Electronic Publication: 2022 Aug 01.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/genetics
Humans ; Immunoglobulin A/genetics ; Immunoglobulin A/metabolism ; Immunophenotyping ; In Situ Hybridization, Fluorescence/methods ; Plasma Cells
Czasopismo naukowe
Tytuł:
Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients.
Autorzy:
Rafae A; Department of Internal Medicine, McLaren Flint-Michigan State University, Flint, MI, USA. Electronic address: .
Ehsan H; Levine Cancer Institute, Charlotte, NC, USA.
Wahab A; Internal Medicine/Hospital Medicine Department, University of Alabama at Birmingham, Montgomery, AL, USA.
Khan SI; SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
Khan I; Bolan Medical College, Quetta, Pakistan.
Ashraf S; Sharif Medical and Dental College, Lahore, Pakistan.
Ali S; Department of Internal Medicine, Ascension St. Agnes Hospital, Baltimore, MD, USA.
Khalid F; Department of Internal Medicine, Monmouth Medical Center, Long Branch, NJ, USA.
Neupane K; Department of Internal Medicine, Jacobi Medical Center, Bronx, NY, USA.
Valent J; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Khouri J; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Samaras C; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Mazzoni S; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Anwer F; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Pokaż więcej
Źródło:
Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2022 Aug; Vol. 176, pp. 103744. Date of Electronic Publication: 2022 Jun 15.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib ; Dexamethasone ; Humans ; Lenalidomide/therapeutic use ; Transplantation, Autologous
Czasopismo naukowe
Tytuł:
The role of VWF/FVIII in thrombosis and cancer progression in multiple myeloma and other hematological malignancies.
Autorzy:
Comerford C; Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.; Department of Haematology, Beaumont Hospital, Dublin, Ireland.
Glavey S; Department of Haematology, Beaumont Hospital, Dublin, Ireland.; School of Pathology, Royal College of Surgeons in Ireland, Dublin, Ireland.
Quinn J; Department of Haematology, Beaumont Hospital, Dublin, Ireland.; School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland.
O'Sullivan JM; Irish Centre for Vascular Biology, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.
Pokaż więcej
Źródło:
Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2022 Aug; Vol. 20 (8), pp. 1766-1777. Date of Electronic Publication: 2022 Jun 23.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hematologic Neoplasms*/complications
Hematologic Neoplasms*/drug therapy
Hemostatics*
Multiple Myeloma*/complications
Multiple Myeloma*/drug therapy
Thrombosis*
ADAMTS13 Protein ; Factor VIII/therapeutic use ; Humans ; von Willebrand Factor/metabolism
Czasopismo naukowe
Tytuł:
Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma.
Autorzy:
Böckle D; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.
Tabares P; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.; Interdisciplinary Center for Clinical Research Laboratory, Würzburg University Hospital, Würzburg, Germany.
Zhou X; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.
Schimanski S; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.
Steinhardt MJ; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.
Bittrich M; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.
Seebacher E; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.; Interdisciplinary Center for Clinical Research Laboratory, Würzburg University Hospital, Würzburg, Germany.
Ulbrich M; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.; Interdisciplinary Center for Clinical Research Laboratory, Würzburg University Hospital, Würzburg, Germany.
Wilnit A; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.; Interdisciplinary Center for Clinical Research Laboratory, Würzburg University Hospital, Würzburg, Germany.
Metz C; Department of Radiology, Würzburg University Hospital, Würzburg, Germany.
Heidemeier A; Department of Radiology, Würzburg University Hospital, Würzburg, Germany.
Bley T; Department of Radiology, Würzburg University Hospital, Würzburg, Germany.
Werner R; Department of Nuclear Medicine, Würzburg University Hospital, Würzburg, Germany.
Buck A; Department of Nuclear Medicine, Würzburg University Hospital, Würzburg, Germany.
Einsele H; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.
Kortüm KM; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.
Beilhack A; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.; Interdisciplinary Center for Clinical Research Laboratory, Würzburg University Hospital, Würzburg, Germany.
Rasche L; Division of Oncology and Hematology, Department of Internal Medicine II, Würzburg University Hospital, Würzburg, Germany.; Mildred Scheel Early Career Center, Würzburg University Hospital, Würzburg, Germany.
Pokaż więcej
Źródło:
British journal of haematology [Br J Haematol] 2022 Aug; Vol. 198 (3), pp. 515-522. Date of Electronic Publication: 2022 May 18.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Flow Cytometry*/methods
Multiple Myeloma*/diagnostic imaging
Multiple Myeloma*/drug therapy
Humans ; Magnetic Resonance Imaging ; Neoplasm, Residual/diagnostic imaging ; Positron-Emission Tomography ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort.
Autorzy:
Chalayer E; Department of Haematology and Cell Therapy, Centre Hospitalo-Universtiaire de Saint Etienne, Saint Etienne, France.; U1059 INSERM, Team SAINBIOSE DVH, Université Jean Monnet Saint-Etienne, Saint-Etienne, France.
Talbot A; Hopital Saint Louis, Department of Haematology, Paris, France.
Frenzel L; Department of Haematology, Institut Necker, Paris, France.
Karlin L; Department of Haematology, Hospices Civils de Lyon, Lyon, France.
Collet P; Department of Haematology and Cell Therapy, Institut de Cancerologie Lucien Neuwirth, St Priest en Jarez, France.
Guyotat D; Department of Haematology and Cell Therapy, Institut de Cancerologie Lucien Neuwirth, St Priest en Jarez, France.
Attal M; Department of Haematology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France.
Leleu X; Department of Haematology, Centre Hospitalier et Universitaire la Miletrie, Poitiers, France.
Tardy B; Centre d'investigation Clinique INSERM CIC 1408, CHU Saint Etienne, France.
Pokaż więcej
Źródło:
Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2022 Aug; Vol. 20 (8), pp. 1859-1867. Date of Electronic Publication: 2022 May 24.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Venous Thromboembolism*/diagnosis
Venous Thromboembolism*/epidemiology
Venous Thromboembolism*/prevention & control
Anticoagulants/therapeutic use ; Bortezomib/adverse effects ; Dexamethasone/adverse effects ; Humans ; Lenalidomide/adverse effects ; gamma-Globulins/therapeutic use
Czasopismo naukowe
Tytuł:
Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma.
Autorzy:
Cho H; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Shin S; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Chung H; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Jang JE; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim YR; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Cheong JW; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Min YH; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Lee ST; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Choi JR; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Kim JS; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea.
Pokaż więcej
Źródło:
British journal of haematology [Br J Haematol] 2022 Aug; Vol. 198 (3), pp. 503-514. Date of Electronic Publication: 2022 May 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/diagnosis
Multiple Myeloma*/genetics
Multiple Myeloma*/therapy
High-Throughput Nucleotide Sequencing ; Humans ; Neoplasm, Residual/drug therapy ; Prognosis ; Transplantation, Autologous
Czasopismo naukowe
Tytuł:
Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
Autorzy:
Rybinski B; Department of Internal Medicine, University of Maryland Medical Center, Baltimore, MD, USA.
Rapoport AP; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Badros AZ; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Hardy N; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
Kocoglu M; Department of Medicine, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.. Electronic address: .
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Aug; Vol. 22 (8), pp. e716-e729. Date of Electronic Publication: 2022 Mar 28.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Heterocyclic Compounds*/pharmacology
Heterocyclic Compounds*/therapeutic use
Lenalidomide*/therapeutic use
Multiple Myeloma*/drug therapy
Benzylamines/therapeutic use ; COVID-19 ; Cyclams/therapeutic use ; Cyclophosphamide/therapeutic use ; Hematopoietic Stem Cell Mobilization/methods ; Humans ; Pandemics ; Retrospective Studies ; Transplantation, Autologous
Czasopismo naukowe
Tytuł:
The Immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells.
Autorzy:
Perini T; Age related Diseases Unit, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy.; University Vita-Salute San Raffaele, Milano, Italy.; Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy.
Materozzi M; Age related Diseases Unit, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy.; Department of Medicine, Surgery and Neurosciences, University of Siena, Italy.
Milan E; Age related Diseases Unit, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy.; University Vita-Salute San Raffaele, Milano, Italy.
Pokaż więcej
Źródło:
The FEBS journal [FEBS J] 2022 Aug; Vol. 289 (15), pp. 4383-4397. Date of Electronic Publication: 2021 Jun 23.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Multiple Myeloma*/genetics
Multiple Myeloma*/metabolism
Multiple Myeloma*/pathology
Plasma Cells*/metabolism
Carcinogenesis/genetics ; Endoplasmic Reticulum/metabolism ; Homeostasis ; Humans ; Oncogenes
Czasopismo naukowe
Tytuł:
Identification of clinical implications and potential prognostic models of chromatin regulator mutations in multiple myeloma.
Autorzy:
Zhang L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Zhang R; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Wang J; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Chen Y; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Qiao C; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Shi Q; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Jin Y; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Shen X; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Li J; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China.
Chen L; Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, 210029, China. .
Pokaż więcej
Źródło:
Clinical epigenetics [Clin Epigenetics] 2022 Jul 23; Vol. 14 (1), pp. 93. Date of Electronic Publication: 2022 Jul 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/genetics
Chromatin ; DNA Methylation ; Humans ; Mutation ; Prognosis
Czasopismo naukowe
Tytuł:
Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients.
Autorzy:
Dragoș ML; Biology Department, Faculty of Biology, 'Alexandru Ioan Cuza' University of Iasi, 700506 Iasi, Romania.
Ivanov IC; Molecular Diagnosis Department, Regional Institute of Oncology, 700483 Iasi, Romania.
Mențel M; Center for Fundamental Research and Experimental Development in Translation Medicine-TRANSCEND, Regional Institute of Oncology, 700483 Iasi, Romania.; Immunophenotyping Department, Regional Institute of Oncology, 700483 Iasi, Romania.
Văcărean-Trandafir IC; Center for Fundamental Research and Experimental Development in Translation Medicine-TRANSCEND, Regional Institute of Oncology, 700483 Iasi, Romania.
Sireteanu A; Molecular Diagnosis Department, Regional Institute of Oncology, 700483 Iasi, Romania.
Titianu AA; Department of Hematology, Regional Institute of Oncology, 700483 Iasi, Romania.; Department of Hematology, 'Grigore T. Popa' University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania.
Dăscălescu AS; Department of Hematology, Regional Institute of Oncology, 700483 Iasi, Romania.; Department of Hematology, 'Grigore T. Popa' University of Medicine and Pharmacy, 16 University Street, 700115 Iasi, Romania.
Stache AB; Biology Department, Faculty of Biology, 'Alexandru Ioan Cuza' University of Iasi, 700506 Iasi, Romania.; Molecular Diagnosis Department, Regional Institute of Oncology, 700483 Iasi, Romania.
Jitaru D; Biology Department, Faculty of Biology, 'Alexandru Ioan Cuza' University of Iasi, 700506 Iasi, Romania.
Gorgan DL; Biology Department, Faculty of Biology, 'Alexandru Ioan Cuza' University of Iasi, 700506 Iasi, Romania.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2022 Jul 07; Vol. 23 (14). Date of Electronic Publication: 2022 Jul 07.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/genetics
Multiple Myeloma*/metabolism
Bone Marrow/metabolism ; DNA Copy Number Variations/genetics ; Flow Cytometry ; Humans ; Prognosis
Czasopismo naukowe
Tytuł:
Chidamide and venetoclax synergistically exert cytotoxicity on multiple myeloma by upregulating BIM expression.
Autorzy:
Cao L; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China.
Chen Q; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China.
Gu H; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China.
Li Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China.
Cao W; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China.
Liu Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China.
Qu J; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China.
Hou Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China.
Chen J; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China.
Zhang E; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China.; Institute of Hematology, Zhejiang University, Hangzhou, China.; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China.
He J; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China. .; Institute of Hematology, Zhejiang University, Hangzhou, China. .; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China. .
Cai Z; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Rd, Hangzhou, 310003, Zhejiang, China. .; Institute of Hematology, Zhejiang University, Hangzhou, China. .; Zhejiang Laboratory for Systems and Precision Medicine, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, China. .
Pokaż więcej
Źródło:
Clinical epigenetics [Clin Epigenetics] 2022 Jul 07; Vol. 14 (1), pp. 84. Date of Electronic Publication: 2022 Jul 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Multiple Myeloma*/drug therapy
Multiple Myeloma*/genetics
Multiple Myeloma*/pathology
Aminopyridines ; Animals ; Apoptosis ; Benzamides ; Bridged Bicyclo Compounds, Heterocyclic ; Cell Line, Tumor ; DNA Methylation ; Humans ; Mice ; Neoplasm Recurrence, Local/genetics ; Sulfonamides
Czasopismo naukowe
Tytuł:
Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK.
Autorzy:
Salimi A; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.; Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Center (UGMLC), Philipps University Marburg, German Center for Lung Research (DZL) Marburg, Marburg, Germany.
Schroeder KM; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Schemionek-Reinders M; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Vieri M; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Maletzke S; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Gezer D; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Masouleh BK; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
Appelmann I; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Jul 06; Vol. 22 (1), pp. 735. Date of Electronic Publication: 2022 Jul 06.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Multiple Myeloma*/metabolism
Proteasome Inhibitors*/pharmacology
Proteasome Inhibitors*/therapeutic use
Apoptosis ; Autophagy ; Benzamides ; Cell Line, Tumor ; Endoribonucleases ; Humans ; Proteasome Endopeptidase Complex/metabolism ; Protein Serine-Threonine Kinases ; Pyridines ; Pyrimidines
Czasopismo naukowe
Tytuł:
Diabetes mellitus and multiple myeloma; common features of two distinct entities.
Autorzy:
Tentolouris A; First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Ntanasis-Stathopoulos I; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.
Eleftheriadou I; First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Malandrakis P; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.
Tzeravini E; First Department of Propaedeutic Internal Medicine and Diabetes Center, School of Medicine, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Gavriatopoulou M; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece.
Pokaż więcej
Źródło:
Diabetes/metabolism research and reviews [Diabetes Metab Res Rev] 2022 Jul; Vol. 38 (5), pp. e3535. Date of Electronic Publication: 2022 May 25.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Diabetes Mellitus, Type 2*/chemically induced
Diabetes Mellitus, Type 2*/complications
Diabetes Mellitus, Type 2*/drug therapy
Metformin*/therapeutic use
Multiple Myeloma*/chemically induced
Multiple Myeloma*/complications
Multiple Myeloma*/drug therapy
Humans ; Hypoglycemic Agents/adverse effects ; Pioglitazone/therapeutic use
Czasopismo naukowe
Tytuł:
Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
Autorzy:
Wang YT; Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical College of Peking University, Beijing, China.
Bao L; Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical College of Peking University, Beijing, China.
Chu B; Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical College of Peking University, Beijing, China.
Chen XH; Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical College of Peking University, Beijing, China.
Lu MQ; Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical College of Peking University, Beijing, China.
Shi L; Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical College of Peking University, Beijing, China.
Gao S; Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical College of Peking University, Beijing, China.
Fang LJ; Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical College of Peking University, Beijing, China.
Xiang QQ; Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical College of Peking University, Beijing, China.
Ding YH; Department of Hematology, Beijing Jishuitan Hospital, 4th Clinical Medical College of Peking University, Beijing, China.
Pokaż więcej
Źródło:
Journal of clinical laboratory analysis [J Clin Lab Anal] 2022 Jul; Vol. 36 (7), pp. e24375. Date of Electronic Publication: 2022 Mar 30.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/drug therapy
Multiple Myeloma*/genetics
Chromosome Aberrations ; Humans ; In Situ Hybridization, Fluorescence ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Highly expressed genes in multiple myeloma cells - what can they tell us about the disease?
Autorzy:
Børset M; Department of Clinical and Molecular Medicine, Center for Myeloma Research, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.; Department of Immunology and Transfusion Medicine, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Elsaadi S; Department of Clinical and Molecular Medicine, Center for Myeloma Research, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Vandsemb EN; Department of Clinical and Molecular Medicine, Center for Myeloma Research, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Hess ES; Department of Clinical and Molecular Medicine, Center for Myeloma Research, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Steiro IJ; Department of Clinical and Molecular Medicine, Center for Myeloma Research, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Cocera Fernandez M; Department of Clinical and Molecular Medicine, Center for Myeloma Research, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Sponaas AM; Department of Clinical and Molecular Medicine, Center for Myeloma Research, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
Abdollahi P; Department of Clinical and Molecular Medicine, Center for Myeloma Research, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.; Laboratory Clinic, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2022 Jul; Vol. 109 (1), pp. 31-40. Date of Electronic Publication: 2022 Mar 20.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/genetics
Multiple Myeloma*/metabolism
Humans ; Neoplasm Proteins/genetics ; Neoplasm Proteins/metabolism ; Oncogene Proteins/genetics ; Oncogene Proteins/metabolism ; Oncogenes ; Plasma Cells/pathology ; Proteasome Endopeptidase Complex/metabolism ; Protein Tyrosine Phosphatases/genetics ; Protein Tyrosine Phosphatases/metabolism ; RNA, Messenger/metabolism
Czasopismo naukowe
Tytuł:
The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated?
Autorzy:
Gao L; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Liu Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Li Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Feng L; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Wang Z; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Wen L; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Wang F; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Huang X; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Lu J; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. Electronic address: .
Lai Y; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. Electronic address: .
Pokaż więcej
Źródło:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2022 Jul; Vol. 22 (7), pp. 535-544. Date of Electronic Publication: 2022 Jan 31.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/diagnosis
Multiple Myeloma*/drug therapy
Multiple Myeloma*/genetics
Bortezomib/therapeutic use ; Chromosome Aberrations ; DNA Copy Number Variations ; Humans ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Association between Kidney Function, Proteinuria and the Risk of Multiple Myeloma: A Population-Based Retrospective Cohort Study in South Korea.
Autorzy:
Choi T; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University, Durham, NC, USA.
Ahn W; Division of Nephrology, Department of Medicine, Columbia University, NY, USA.
Shin DW; Department of Family Medicine & Supportive Care Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.; Department of Digital Health, SAIHST, Sungkyunkwan University, Seoul, Korea.
Han K; Department of Statistics and Actuarial Science, College of Natural Sciences, Soongsil University, Seoul, Korea.
Kim D; Department of Biostatistics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Chun S; International Healthcare Center, Samsung Medical Center, Seoul, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2022 Jul; Vol. 54 (3), pp. 926-936. Date of Electronic Publication: 2021 Sep 27.
Typ publikacji:
Journal Article
MeSH Terms:
Multiple Myeloma*/complications
Multiple Myeloma*/epidemiology
Adult ; Cohort Studies ; Humans ; Kidney ; Proteinuria/diagnosis ; Proteinuria/epidemiology ; Proteinuria/etiology ; Republic of Korea/epidemiology ; Retrospective Studies ; Risk Factors
Czasopismo naukowe
Tytuł:
Outpatient autologous stem cell transplantation in Royal Hobart Hospital, Tasmania: a single-centre, retrospective review in the Australian setting.
Autorzy:
Tan XN; Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.; Faculty of Medicine Dentistry and Health Sciences, University of Western Australia, Perth, Western Australia, Australia.; Department of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.
Yew CY; Department of Anaesthesia, Armadale Health Service, Perth, Western Australia, Australia.; Department of Anaesthesia, Royal Hobart Hospital, Hobart, Tasmania, Australia.; Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
Ragg SJ; Department of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.; University of Tasmania, Australia.
Harrup RA; Department of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.; University of Tasmania, Australia.
Johnston AM; Department of Haematology, Royal Hobart Hospital, Hobart, Tasmania, Australia.; University of Tasmania, Australia.
Pokaż więcej
Źródło:
Internal medicine journal [Intern Med J] 2022 Jul; Vol. 52 (7), pp. 1242-1250. Date of Electronic Publication: 2022 May 31.
Typ publikacji:
Journal Article
MeSH Terms:
Febrile Neutropenia*/drug therapy
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/drug therapy
Multiple Myeloma*/therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Australia ; Hospitals ; Humans ; Melphalan ; Outpatients ; Retrospective Studies ; Stem Cell Transplantation ; Tasmania/epidemiology ; Transplantation Conditioning ; Transplantation, Autologous
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz